Clinical use of aclidinium in patients with COPD

International Journal of COPD

Volumn 9, Issue , 2014, Pages 369-379

  Reid, Debra J ^a   Carlson, Alexa A ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Aclidinium; Anticholinergic; Antimuscarinic; Chronic obstructive pulmonary disease

Indexed keywords

ACLIDINIUM BROMIDE; CORTICOSTEROID; FORMOTEROL; MOXIFLOXACIN; PLACEBO; PREDNISONE; TIOTROPIUM BROMIDE;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ANTICHOLINERGIC SYNDROME; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; DEVICE COMPARISON; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG APPROVAL; DRUG CHOICE; DRUG DELIVERY DEVICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; NONHUMAN; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; RHINOSINUSITIS; SINGLE DRUG DOSE; STEADY STATE; TACHYCARDIA; URINARY TRACT INFECTION; XEROSTOMIA;

ACLIDINIUM; ANTICHOLINERGIC; ANTIMUSCARINIC; CHRONIC OBSTRUCTIVE PULMONARY DISEASE;

ANIMALS; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME; TROPANES;

EID: 84899734870     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S40193     Document Type: Review

References (35)

1. Centers for Disease Control and Prevention (CDC). Chronic obstructive pulmonary disease among adults-United States, 2001. MMWR e Mortal Wkly Rep. 2012; 61(46): 938-943.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD (GOLD) 2013. Available from: http://www. goldcopd. org/uploads/users/files/GOLD_Report_2014_Jan23. pdf. Accessed January 28, 2014.
3. Williams DM, Bourdet SV. Chronic obstructive pulmonary disease. In: DiPiro JT, Talbert RL, Yee GC, Matze GR, Wells BG, Posey ML, editors. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York, NY: McGraw-Hill; 2011: 471-496. Available from: http://www. accesspharmacy. com/content. aspx?aID=7975888. Accessed November 15, 2013.
4. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006; 27(1): 188-207.
5. Tudorza™ Pressair™ (aclidinium bromide inhalation powder) [product information]. St Louis, MO: Forest Pharmaceuticals, Inc.; 2012. Available from: http://www. frx. com/pi/tudorza_pi. pdf. Accessed on March 6, 2014.
6. Belmonte K. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2(4): 297-304.
7. Gavaldà A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther. 2009; 331(2): 740-751.
8. Prat M, Fernández D, Buil MA, et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2. 2. 2]octane bromide (aclidinium bromide). J Med Chem. 2009; 52(16): 5076-5092.
9. Lasseter K, Dilzer S, Jansat JM, Garcia Gil E, Caracta CF, Ortiz S. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther. 2012; 25(2): 193-199.
10. Jansat JM, Lamarca R, Gil EG, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther. 2009; 47(7): 460-468.
11. Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest. 2012; 141(3): 745-752.
12. Spiriva® HandiHaler® (tiotropium bromide inhalation powder) [product information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2013.
13. Schmid K, Pascual S, Gil EG, Ortiz S, Jansat JM. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial. Clin Ther. 2010; 32(10): 1798-1812.
14. Joos GF, Schelfhout VJ, Pauwels RA, et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010; 104(6): 865-872.
15. Chanez P, Burge PS, Dahl R, et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2010; 23(1): 15-21.
16. Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD. 2010; 7(5): 331-336.
17. Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011; 12: 55.
18. Singh D, Magnussen H, Kirsten A, et al. A randomised, placebo-and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther. 2012; 25(3): 248-253.
19. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012; 40(4): 830-836.
20. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD Istudy investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012; 9(2): 90-101.
21. D'Urzo A, Kerwin E, Rennard S, He T, Gil EG, Caracta C. One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. COPD. 2013; 10(4): 500-510.
22. Rennard SI, Scanlon PD, Ferguson GT, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig. 2013; 33(12): 893-904.
23. Beier J, Kirsten A, Mróz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013; 10(4): 511-522.
24. Gelb AF, Tashkin DP, Make BJ, Zhong X, Garcia Gil E, Caracta C; LAS-MD-35 study investigators. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respir Med. 2013; 107(12): 1957-1965.
25. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005; 2(1): 111-124.
26. Jones PW. St George's Respiratory Questionnaire: MCID. COPD. 2005; 2(1): 75-79.
27. Mahler DA, WItek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005; 2(1): 111-124.
28. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008; 300(12): 1439-1450.
29. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15): 1543-1554.
30. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium-the FDA's conclusions. N Engl J Med. 2010; 363(12): 1097-1099.
31. Lasseter KC, Aubets J, Chuecos F, Gil EG. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. J Clin Pharmacol. 2011; 51(6): 923-932.
32. World Health Organization (WHO). Adherence to Long-term Therapies Evidence for Action. Geneva: WHO; 2003. Available from: http://www. who. int/chp/knowledge/publications/adherence_report/en/. Accessed January 29, 2014.
33. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008; 63(9): 831-838.
34. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009; 64(11): 939-943.
35. Van der Palen J, Ginko T, Kroker A, et al. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv. 2013; 10(8): 1023-1031.